This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.
This study was a prospective, multicenter, non-interventional, real-world study. The study will be divided into two cohorts: Cohort 1 is the younger cohort (aged ≥ 18 and \< 60 years at the start of treatment); Cohort 2 is the older cohort (aged ≥ 60 years at the start of treatment). Patients in this study will receive obinutuzumab-contained regimens according to the investigators' clinical opinion.
Study Type
OBSERVATIONAL
Enrollment
400
obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Efficacy Endpoints
The best objective response rate (ORR), and CR rate; ORR and CR rate at the end of treatment; DCR, DoR, TTNT, PFS, DFS, and OS.
Time frame: 12 months
Safety Endpoints
All AEs, SAEs, Grade 3 AEs, and all other safety variables, including vital signs, Physical examination results, and laboratory parameters.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The First People's hospital of Changzhou
Changzhou, Jiangsu, China
Huai'an First People's hospital
Huai'an, Jiangsu, China
Jiangyin People's Hospital
Jiangyin, Jiangsu, China
Jingjiang People's Hospital
Jingjiang, Jiangsu, China
The first people's hospital of Lianyungang
Lianyungang, Jiangsu, China
The second people's hospital of Lianyungang
Lianyungang, Jiangsu, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
...and 15 more locations